The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Donor lymphocyte infusion (DLI) is often used to enhance the graft-versus-leukemia (GVL) effect after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we first evaluated the impact of the cell composition of a modified DLI (mDLI) on the prognoses of patients. A total of 194 patients undergoing allo-HSCT were enrolled and received mDLI for various clinical reasons. The infused cellular components of the mDLI were examined by flow cytometry. The results showed that infusion with a lower dose of CD14(+) cells (<0.33 × 10(8) /kg) was an independent risk factor for the occurrence of II-IV acute graft-versus-host disease (aGVHD) (HR = 0.104, p = 0.032) in human leukoctye antigen-identical transplant patients. In addition, a dose of CD14(+) cells greater than the 50th percentile was associated with a lower incidence of hematological relapse and longer disease-free survival (DFS) after the mDLI (relapse: HR = 0.193, p = 0.007; DFS: HR = 0.259, p = 0.016). However, we also found that a greater number of CD14(+) cells were an independent risk factor for II-IV aGVHD (HR = 1.758, p = 0.034) in haploidentical allo-HSCT. In conclusion, our data were the first to demonstrate that the cell composition of a 56 mDLI played a distinct role in different types of allo-HSCT. This finding provided a novel approach for the development of cellular therapies by manipulating the components of infused cells.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Clinical transplantation - 28(2014), 8 vom: 15. Aug., Seite 926-34 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zhao, Xiao-Su [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Allogeneic hematopoietic stem cell transplantation |
|---|
| Anmerkungen: |
Date Completed 12.05.2015 Date Revised 16.11.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ctr.12404 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM239203402 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM239203402 | ||
| 003 | DE-627 | ||
| 005 | 20231224115433.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ctr.12404 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0797.xml |
| 035 | |a (DE-627)NLM239203402 | ||
| 035 | |a (NLM)24931494 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zhao, Xiao-Su |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The cell composition of infused donor lymphocyte has different impact in different types of allogeneic hematopoietic stem cell transplantation |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2015 | ||
| 500 | |a Date Revised 16.11.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Donor lymphocyte infusion (DLI) is often used to enhance the graft-versus-leukemia (GVL) effect after allogeneic hematopoietic stem cell transplantation (allo-HSCT). In this study, we first evaluated the impact of the cell composition of a modified DLI (mDLI) on the prognoses of patients. A total of 194 patients undergoing allo-HSCT were enrolled and received mDLI for various clinical reasons. The infused cellular components of the mDLI were examined by flow cytometry. The results showed that infusion with a lower dose of CD14(+) cells (<0.33 × 10(8) /kg) was an independent risk factor for the occurrence of II-IV acute graft-versus-host disease (aGVHD) (HR = 0.104, p = 0.032) in human leukoctye antigen-identical transplant patients. In addition, a dose of CD14(+) cells greater than the 50th percentile was associated with a lower incidence of hematological relapse and longer disease-free survival (DFS) after the mDLI (relapse: HR = 0.193, p = 0.007; DFS: HR = 0.259, p = 0.016). However, we also found that a greater number of CD14(+) cells were an independent risk factor for II-IV aGVHD (HR = 1.758, p = 0.034) in haploidentical allo-HSCT. In conclusion, our data were the first to demonstrate that the cell composition of a 56 mDLI played a distinct role in different types of allo-HSCT. This finding provided a novel approach for the development of cellular therapies by manipulating the components of infused cells | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a composition | |
| 650 | 4 | |a donor lymphocyte infusion | |
| 650 | 4 | |a graft-versus-host disease | |
| 650 | 4 | |a outcome | |
| 650 | 7 | |a Lipopolysaccharide Receptors |2 NLM | |
| 700 | 1 | |a Wang, Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Chen-Hua |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jing-Zhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Xiao-Hui |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Lan-Ping |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Kai-Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Xiao-Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical transplantation |d 1987 |g 28(2014), 8 vom: 15. Aug., Seite 926-34 |w (DE-627)NLM07493306X |x 1399-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2014 |g number:8 |g day:15 |g month:08 |g pages:926-34 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ctr.12404 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2014 |e 8 |b 15 |c 08 |h 926-34 | ||